FDA 因严重无菌与卫生缺陷向中国制药商发出警告信
Warning Letter to Chinese Manufacturer due to serious Sterility and Hygiene Deficiencies
FDA 在 2024 年 11 月对一家中国制药商的检查中发现严重 GMP 缺陷,包括卫生条件恶劣、缺乏经验证的灭菌方法,以及未对标注为无菌的产品进行无菌检测。FDA 于 1 月 21 日要求企业召回受影响产品,企业于 2025 年 2 月 11 日实施召回。FDA 认定其整个质量体系不足,并要求采取整改措施以恢复 GMP 合规。
材料汇总了 FDA 检查发现的卫生、灭菌与无菌检测缺陷及后续召回进展,可作为无菌保障环节的案例对照。
The FDA found serious GMP deficiencies during an inspection of a Chinese pharmaceutical manufacturer in November 2024. These include, above all, inadequate hygiene and assurance of product sterility. For example, medicinal products were labelled as 'sterile' although neither sterilisation nor sterility tests were carried out. 1. Insanitary manufacturing conditionsThe FDA inspectors assessed the manufacturing facility as ina state of disrepair, not cleaned and not maintained. Specifically, the following deficiencies were found, among others: Numerous dead insects in tubing used to transfer active ingredients and in the storage containers of these tubings. Unknown foreign particles in a solution that was fed into the filling line Product transfer hoses were cracked, leaking, discoloured or had residues Contamination of bulk containers of ingredients or intermediates with hair, particles or insects The ceilings above open filling and packaging systems were visibly soiled and damaged.2. Inadequate aseptic procedures and lack of sterilisationAlthough the products were declared as 'sterile', the company had discontinued the sterilisation previously used without introducing a new validated method. There was neither a validated sterilisation method nor environmental monitoring. Basic requirements for hygienic clothing were also not met.3. No sterility testingAccording to the FDA, no sterility testing was carried out for the products labelled as 'sterile'. This means that there is no assurance that the products actually fulfil the sterility and pyrogen-free requirements.4. No identity check and lack of testing of raw materialsThe company relied entirely on manufacturer certificates (COAs) without carrying out its own identity checks or verifying the quality specifications. The suppliers were not qualified. In addition, the water used for production was not tested for microbial contamination. 5. Inadequate stability programmeDespite a declared expiry date, data was only available for a shorter period. The company did not have an ongoing stability programme to prove the shelf life.ConsequencesOn 21 January, the FDA asked the company to recall affected products from the market, which it did on 11 February 2025. The FDA assessed the manufacturer's entire quality system as inadequate and demanded extensive corrective measures to restore GMP compliance. The Warning Letter to the Chinese manufacturer can be found on the FDA website.
来源:ECA GMP News · gmp-compliance.org